

December 24, 2025  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

**SymBio Announces Exclusive Global License Agreement with Penn State Research  
Foundation for Treatment of Polyomavirus Infections with IV BCV**

Tokyo, Japan, December 24, 2025 – SymBio Pharmaceuticals Limited (hereinafter “SymBio” or the “Company”) today announced that it has entered into a license agreement with Penn State Research Foundation to secure global exclusive rights for the development and commercialization of intravenous brincidofovir (IV BCV) for the treatment of polyomavirus infections. This agreement relates to joint research conducted with Penn State College of Medicine and patent applications made by SymBio based on the results of that research.

Under this agreement, SymBio has acquired the exclusive global license based on the relevant patent applications to develop and commercialize IV BCV, and will accelerate activities toward early commercialization. The international phase of the patent application process under the Patent Cooperation Treaty (PCT) has been initiated.

Currently, there is no established standard of care for the treatment of polyomavirus infections (such as BK virus nephropathy (BKVN) following kidney transplantation and progressive multifocal leukoencephalopathy (PML)), and there is a strong unmet medical need for new therapies. The results of the joint research were published in *mBio* in July 2024, suggesting that IV BCV has the potential to become a promising treatment option for polyomavirus infections.

Statement from Fuminori Yoshida, President and CEO: “BK virus nephropathy following kidney transplantation and progressive multifocal leukoencephalopathy caused by JC virus infection are serious conditions with no effective treatments. We will move forward swiftly with development to make IV BCV available to patients as soon as possible.”

There is no material impact on the consolidated financial outlook for the fiscal year ending December 2025.

[Contact] Investor Relations Tel: +81(0)3 5472 1125

#### Notes

##### **About Polyomavirus Infections**

##### **BK Virus Nephropathy (BKVN):**

A serious complication in immunosuppressed patients after kidney transplantation, caused by reactivation of BK virus, leading to allograft injury (inflammation, decreased function, and ultimately graft loss). BK virus infects 80–90% of adults and typically remains latent in the urinary tract without symptoms. Immunosuppressive therapy (e.g., after kidney transplant) can allow the virus to escape control and reactivate. The number of patients with BKVN after kidney transplantation is estimated at approximately 8,000 across Japan, the United States, and Europe.

##### **Progressive Multifocal Leukoencephalopathy (PML):**

A rare, life-threatening disease with high mortality caused by JC virus reactivation in patients with immunodeficiency and impaired cellular immunity. There is currently no standard therapy, and new treatments are urgently needed.

##### **Joint Research with Penn State University College of Medicine**

Please refer to the published findings from Penn State University College of Medicine on the inhibitory effect of the antiviral brincidofovir on the production of infectious polyomavirus particles (link: [Penn State College of Medicine announces findings](#)).

##### **BCV Business Strategy Based on Three Therapeutic Pillars**

Since obtaining the global license for BCV in September 2019, SymBio has advanced collaborative research with world-class institutions to unlock its potential across three therapeutic areas. We are currently focusing our development resources on: (1) viral infections following hematopoietic stem cell transplantation; (2) hematologic and solid tumors; and (3) neurodegenerative diseases. By pursuing development and commercialization globally across these three pillars, SymBio aims to maximize the value of the BCV franchise.